A house divided: JPMorgan de-risks into Sept. 16, wealth strategists see a hike, and Goldman still leans hold.
Author: Trading Stocks Now
Cytokinetics Just Won a Key Trial. Is the Stock Still Worth Buying?
August 31, 2026 Aficamten’s ACACIA win removes the binary risk that has kept a lid on the stock. Here is…
Microsoft Is Finally Turning AI Spending Into Revenue
August 31, 2026 Azure’s 43% growth quarter ended a year-long debate. Now ask whether the market has already priced it…
The Regulation Nobody Talks About Is Building the Edge
Data-sovereignty laws are pushing some workloads out of the cloud and into local hardware. That is a real edge computing…
Copper Near $6.55, FCX Near Highs: Monday’s PMI Test
A second sub-50 China reading could hit commodities and EM risk just as positioning looks stretched.
Aptiv Is Down 36%. Insiders Just Bought $8M.
August 30, 2026 The backup camera recall wave points to a software problem. Aptiv sells the fix, and its own…
Long the Spread, Not the Barrel
Russia’s diesel export ban runs to Sept. 30. ULSD cracks stay the trade, and complex refiners are the cleaner expression.
HY OAS at 275bp: the number equities must watch
The spread level where credit stops being a tailwind and starts driving asset prices.
Medtronic’s Product Cycle Is Bigger Than the Street Admits
Four straight beats, conservative guidance, and three launches converge before Tuesday’s open.
Dell Reports Tuesday. One Line Decides Everything.
August 29, 2026 AI server revenue of $16.1B in a single quarter was remarkable. The ISG operating margin at 10.5%…